Navigation Links
Teva's 'Patient First' Initiative Highlights Struggle Against High Health Care Costs, Reminds Lawmakers of Reform Goals
Date:8/20/2009

Real Americans Share Experiences, Common Need for Patient-Centric Reform

WASHINGTON, Aug. 20 /PRNewswire-USNewswire/ -- Teva Pharmaceuticals USA, the world's leading generic pharmaceutical company, today announced the start of its "Patient First" project as part of the Year of Affordable Healthcare campaign. The initiative, available at: www.yearofaffordablehealth.com/patients, features a first-hand perspective of everyday Americans as they struggle with the enormous and sometimes insurmountable expense of paying for their prescription medicines.

The Patient First initiative features compelling, real-life stories like that of Rob Day, a father of two from Port Huron, Michigan. At age 19, Rob was diagnosed with Paroxysmal Nocturnal Hemoglobinuria (PNH), an extremely rare blood disorder. As his video and profile demonstrate, Rob has spent half his life waiting for a medicine to treat his rare condition. Now that he finally has it, he can't afford to keep it.

The medicine for his condition, a biologic, is extremely expensive, costing $389,000 a year. Rob knows that he must take this medicine for the rest of his life in order to stay alive but doesn't know how he and his family will continue to be able to afford his care.

An FDA approval pathway for generic biologic drugs that provides real, market-based competition, could yield more affordable versions of these biologic medicines for Rob and millions of other Americans in the years to come. In addition to greater access, the benefit of timely competition will be further incentives for innovative biologic medicines that treat diseases including diabetes, multiple sclerosis, Alzheimer's, Parkinson's, psoriasis and cancer. An approval pathway, like the one supported by the Obama Administration and many members of Congress, would do just that - provide relief to people like Rob while introducing billions of dollars in savings for our healthcare system.

"Rob's story is just one of a number of Patient First stories that chronicle the struggles of patients across America," said Debra Barrett, Senior Vice President of Teva Pharmaceuticals USA. "The common thread is the hope for meaningful health care reform that provides relief to those that need it most. Their stories should remind Congress and the White House of what this debate is all about."

To learn more about Rob's story, and other like his, visit the Patient First initiative on-line at: www.yearofaffordablehealth.com/patients

Teva's Year of Affordable Healthcare is a nationwide campaign to recognize the important role that generic drugs play in providing competitive and more affordable healthcare. In addition, the campaign calls upon federal legislators to enact further reforms, including passage of a competitive regulatory approval pathway for generic biologics to increase American access to affordable and lifesaving medicines.

Individuals and organizations can to lend their voices to the Patient First initiative by contacting the Year of Affordable Healthcare campaign at info@yearofaffordablehealth.com

About the Year of Affordable Healthcare

The Year of Affordable Healthcare campaign (www.yearofaffordablehealth.com) is a nationwide call for increased access to affordable healthcare for American citizens. The program coincides with the 25th anniversary of the landmark Hatch-Waxman Act, which created the modern generic pharmaceutical industry and has saved billions of healthcare dollars. For more information, additional videos and details on upcoming events, please visit the Year of Affordable Healthcare Campaign website at: www.yearofaffordablehealth.com.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

Media Contact: Denise Bradley

Phone: (215) 591-8974

E-mail: Denise.Bradley@tevausa.com


'/>"/>
SOURCE Teva Pharmaceuticals USA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Newer Drug Beats Tamoxifen for Older Breast Cancer Patients
2. Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
3. Tumor size and level of visceral pleura invasion can impact survival of NSCLC patients
4. Study shows carvedilol is effective in preventing variceal bleeding in cirrhotic patients
5. Laurence Barsh, DMD, Founder of Snoring Isn't Sexy, LLC Emphasizes Need to Evaluate and Treat Sleep Patients
6. Iterative reconstruction technique significantly reduces patient radiation dose during CT scans
7. Palliative care intervention for patients with advanced cancer provides quality of life benefits
8. Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme
9. Uninsured Patients to Receive Free Surgeries, Procedures
10. Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units
11. Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: